Company Media Media 2017 In dash to NASH, Immuron targets the gut not the liver

In dash to NASH, Immuron targets the gut not the liver

Cookies and milk or cookies and colostrum? Immuron is targeting inflammatory bacteria in the gut with an engineered colostrum formulation, designed to prevent the liver damage that leads to NASH. https://medcitynews.com/2017/03/dash-to-nash-immuron-targets-gut/

This category is empty! Please try another category or use our search function to find what you are looking for. If you require further assistance please contact us.

Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies.

The company presently has three drug candidates in clinical development and several in early stage preclinical development. Immuron believes its therapeutic drug candidates have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, recurrent Clostridiodes difficile (C.difficle) infections, Enterotoxigenic Escherichia coli (ETEC) infections, Shigellosis (Bacillary dysentery) and travelers’ diarrhea.

Payment Options

Contact Information

Address: Building 10, 25-37 Chapman Street, Blackburn North, VIC 3131 Australia
Phone: +613 8892 4854
Fax: +613 9899 8533

Filter Categories

In dash to NASH, Immuron targets the gut not the liver

Partners

Secure Shopping

Get Connected

About Us

Information

Payment Options

Contact Information